Jul 2 |
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
|
Jun 28 |
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
|
Jun 14 |
Cabaletta Bio slips after early data for lead asset
|
Jun 14 |
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
|
May 29 |
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
|
May 22 |
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
|
May 15 |
Cabaletta Bio GAAP EPS of -$0.51
|
May 15 |
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 13 |
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
May 5 |
Wall Street Breakfast: The Week Ahead
|